Aadi bioscience announces financial results for the third quarter 2024 and provides corporate update

Fyarro® sales of $7.2 million for q3 2024, reflecting 21% year over year sales growth aadi continues to focus on fyarro commercial business and comprehensive strategic review to maximize shareholder value los angeles , nov. 6, 2024 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi) today announced financial results for the third quarter ended september 30, 2024, and provided recent corporate progress. "the third quarter saw strong sales growth for fyarro, backed by continued account momentum, increased demand and a nearly 90 percent reorder rate – all reinforcing the clinical value of fyarro for patients with advanced malignant pecoma," said dave lennon, president and ceo of aadi bioscience.
AADI Ratings Summary
AADI Quant Ranking